Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies.
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies.
复制标题
ACE基因在2型糖尿病学科中的插入/缺失多态性的预后价值：来自非胰岛素依赖糖尿病，高血压，微量珠蛋白尿或蛋白尿，心血管疾病，心血管事件和ramipril（糖尿病），糖尿病（糖尿病），糖尿病（糖尿病） Genetique（Diab2Nephrogene）和Survie，糖尿病DE型糖尿病（Surdiagene）研究。
DOI：
10.2337/dc07-2079
复制
发表时间：
2008-09
期刊：
影响因子：
16.2
通讯作者：
SURDIAGENE Study Group
中科院分区：
文献类型：
--
作者：
Hadjadj S;Fumeron F;Roussel R;Saulnier PJ;Gallois Y;Ankotche A;Travert F;Abi Khalil C;Miot A;Alhenc-Gelas F;Lievre M;Marre M;DIABHYCAR Study Group;DIAB2NEPHROGENE Study Group;SURDIAGENE Study Group
我们测试了ACE插入/缺失多态性的测定是否对2型糖尿病患者的肾脏和心血管疾病有用。研究设计和方法--在非胰岛素依赖型糖尿病、高血压、微量白蛋白尿或蛋白尿、心血管事件和拉米替尼（DIABHYCAR）试验中，根据ACE插入/缺失多态性，对法国参与者（4,912人中的3,126人）的预后进行了4年以上的研究。我们使用了两个法国2型糖尿病患者队列进行重复研究：一项3年随访研究（n = 917; Survie，2型糖尿病和遗传学[SURDIAGENE]研究）和一项糖尿病肾病病例对照研究（n = 1，277; 2型糖尿病肾病和遗传学[DIAB 2NEPHROGENE]研究）。我们研究了插入/缺失多态性对DIABHYCAR试验主要结局（定义为以下事件中的第一个发生：心血管死亡、非致死性心肌梗死、卒中、导致住院的心力衰竭或终末期肾衰竭）及其组成部分的影响。结果-在DIABHYCAR中，主要结局及其大部分组成部分不受ACE插入/缺失基因型的影响。只有肾脏预后受I等位基因的影响（P = 0.03）。ACE基因型对心肌梗死的危险性无明显影响，但随着D等位基因数目的增加，心肌梗死的死亡率增加（P < 0.03）。在SURDIAGENE中，ACE I等位基因与肾脏预后之间的关联性未被复制。在糖尿病肾病中，未发现与肾病相关。结论：我们不能证明ACE插入/缺失多态性对2型糖尿病受试者预后的明显有用性。
OBJECTIVE—We tested whether determination of the ACE insertion/deletion polymorphism is useful for renal and cardiovascular prognoses of type 2 diabetic subjects. RESEARCH DESIGN AND METHODS—The French participants (3,126 of 4,912) in the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) trial were studied for their prognosis over 4 years according to their ACE insertion/deletion polymorphism. We used two cohorts of French type 2 diabetic patients for replication: a 3-year follow-up study (n = 917; Survie, Diabete de type 2 et Genetique [SURDIAGENE] study) and a case-control study on diabetic nephropathy (n = 1,277; Diabete de type 2, Nephropathie et Genetique [DIAB2NEPHROGENE] study). We investigated the effect of the insertion/deletion polymorphism on the primary outcome in the DIABHYCAR trial (defined as the first of the following events to occur: cardiovascular death, nonfatal myocardial infarction, stroke, heart failure leading to hospital admission, or end-stage renal failure) and its components. RESULTS—In DIABHYCAR, the primary outcome and most of its components were not affected by the ACE insertion/deletion genotype. Only renal outcome was favored by the I allele (P = 0.03). The risk of myocardial infarction was not affected by ACE genotype, but the probability of fatal outcome increased with the number of D alleles (P < 0.03). In SURDIAGENE, the association between the ACE I allele and renal outcome was not replicated. In DIAB2NEPHROGENE, no association was found with nephropathy. CONCLUSIONS—We were not able to demonstrate the manifest usefulness of the ACE insertion/deletion polymorphism for the prognosis of type 2 diabetic subjects.
登录
查看更多内容
影响因子：
168.9
作者：
Ruggenenti, P;Perna, A;Remuzzi, G
通讯作者：
Remuzzi, G
影响因子：
13.6
作者：
Hadjadj, S;Belloum, R;Marre, M
通讯作者：
Marre, M
影响因子：
168.9
作者：
Booth, Gillian L.;Kapral, Moira K.;Tu, Jack V.
通讯作者：
Tu, Jack V.
影响因子：
7.7
作者：
Boright, AP;Paterson, AD;Zinman, B
通讯作者：
Zinman, B
DOI：
10.1073/pnas.231476798
发表时间：
2001-11-06
影响因子：
11.1
作者：
Huang, W;Gallois, Y;Alhenc-Gelas, F
通讯作者：
Alhenc-Gelas, F